Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...

The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...

In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...

An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...

The AD-SMART trial – which has started to recruit people aged over 55 with a diagnosis of Alzheimer's or mixed dementia – ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...

Julia Jakl is VP and Business Unit Head, Oncology UK at GSK. With more than a decade of experience across oncology and ...

A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...

Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in ​an all-cash, $1.3 billion deal that will boost its ...

That one chance rests on a set of decisions about data and the systems that hold it. Those decisions are usually made quickly ...